Health-related quality of life as an endpoint in oncology phase I trials: a systematic review

Frédéric Fiteni 1, 2, 3, * Isabelle Le Ray 4, 5 Ahmad Ousmen 6 Nicolas Isambert 7 Amélie Anota 6, 8 Franck Bonnetain 6, 8
* Corresponding author
1 Department of Medical Oncology [Nîmes]
2 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
3 UM - Université de Montpellier
4 Department of Neonatology [Strasbourg]
5 MEB - Department of Medical Epidemiology and Biostatistics
6 Methodology and Quality of Life in Oncology Unit [Besançon]
7 Département d'oncologie médicale [Centre Georges-François Leclerc]
8 French National Platform Quality of Life and Cancer [Dijon]
Abstract : BACKGROUND: Phase I trials aim to identify the recommended dose for further development. Health-related quality of life (HRQoL) could be a complement to the usual National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale to detect adverse events and define the doses. The objective of this study is to review the phase I in oncology which used HRQoL as endpoint. METHODS: A search in PubMed database identified phase I trials in oncology with HRQoL as endpoint, published between January 2012 to May 2016. Hematological and pediatric phase I were excluded. RESULTS: A total of 1333 phase I were identified and 15 trials were identified with HRQoL as endpoint (1.1%). The European Organisation for Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) was the most frequently used instrument: 5 studies (33.3%). The targeted dimensions of HRQoL and the minimal clinically important difference were prespecified in 1 study (6.7%) and 2 studies (13.3%), respectively. Twelve studies (80%) described the statistical approach to analyze HRQoL data. Eight studies used the mean change from baseline (60%) to analyse longitudinal HRQoL data, two the mean score at certain times (13.3%), one the linear mixed model for repeated measures (6.7%), one the time to HRQoL score deterioration (6.7%), one percentage of patient-reported symptoms (6.7%). None of the studies used HRQoL to determine the recommended doses. CONCLUSION: Few phase I studies used HRQoL as endpoint and among studies with HRQoL as endpoint, the methodology of HRQoL measurement and statistical analysis was heterogeneous. HRQoL. endpoint not used for assessing the recommended phase II doses.
Keywords : Recommended phase II dose Phase I trial Endpoint Health-related quality of life
Document type :
Journal articles
Complete list of metadatas

Cited literature [26 references]  Display  Hide  Download
https://www.hal.inserm.fr/inserm-02298801
Contributor : Myriam Bodescot <>
Submitted on : Friday, September 27, 2019 - 11:15:41 AM
Last modification on : Saturday, September 28, 2019 - 1:20:23 AM

File

s12885-019-5579-3.pdf
Publication funded by an institution

Identifiers

Collections

CGFL | VALDAURELLE | FNCLCC | BS | UNIV-MONTPELLIER | IRCM

Citation

Frédéric Fiteni, Isabelle Le Ray, Ahmad Ousmen, Nicolas Isambert, Amélie Anota, et al.. Health-related quality of life as an endpoint in oncology phase I trials: a systematic review. BMC Cancer, BioMed Central, 2019, 19 (1), pp.361. ⟨10.1186/s12885-019-5579-3⟩. ⟨inserm-02298801⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

72

Files downloads

37

Contact

Informations

CCSD